Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Luye Pharma Group: Clinical Trials & FDA Approval Profile

Luye Pharma Group (Global / Institutional) sponsors 19 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 7 active protocols (3 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)290 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Luye Pharma Group
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)19
Active Pipeline (Recruiting Now)7 (3)
Completed vs Stopped Early7 / 0 (0.0%)
Median Closed Actual Enrollment290 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Luye Pharma Group
Hospital Research SiteLocationShared Protocols
Cancer Hospital Chinese Academy of Medical SciencesBeijing2

Explore interactive annual charts and M&A subsidiary rollups in the Luye Pharma Group Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI